ArticleJournal of the American College of Cardiology2015
Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.
Article in Journal of the American College of Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- Computed tomography-guided pericardiocentesis: a systematic review concerning contemporary evidence and future perspectives.Therapeutic advances in cardiovascular disease · 2018Pooled it
- Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.International journal of radiation oncology, biology, physics · 2017Trial
- Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study.The oncologist · 2026Observational
- Long-term mortality and acute complications after percutaneous pericardiocentesis in cancer and noncancer patients presenting with severe pericardial effusion.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Balloon pericardiotomy for malignant pericardial effusion: the PMAP trial.European heart journal · 2026Article
- Role of Multimodal Cardiac Imaging in Pericardial Effusions and Tamponade.Methodist DeBakey cardiovascular journal · 2026Review
- Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology.European journal of heart failure · 2025Article
- In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy.Current oncology (Toronto, Ont.) · 2025Article
- Etiologies, fluid characteristics, and outcomes of pericardiocentesis: a five-year retrospective study from a single center.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Article
- Surgical Management Strategies for Pericardial Effusion-A Systematic Review.Journal of clinical medicine · 2025Review
- Treating a Metastatic Pericardial Tumor.JACC. Case reports · 2025Article
- Safety and Efficacy of Echo- vs. Fluoroscopy-Guided Pericardiocentesis in Cardiac Tamponade.Medicina (Kaunas, Lithuania) · 2025Observational
- An infusion port for recurrent massive pericardial effusion: a case report.European heart journal. Case reports · 2024Article
- Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment.Cancers · 2024Review
- Percutaneous pericardiocentesis using the apical approach: case series and review of the literature.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Review
- Asymptomatic Chronic Large Pericardial Effusions: To Drain or to Observe?Journal of clinical medicine · 2024Review
- What intensivists need to know on cardiac dysfunction in critically ill cancer patients.Intensive care medicine · 2024Article
- Article
- Cardiac Tamponade as an Initial Manifestation of Diffuse Large B-cell Lymphoma One Year after IgG4-related Disease in Remission.Internal medicine (Tokyo, Japan) · 2024Article
- Pericardial effusion in oncological patients: current knowledge and principles of management.Cardio-oncology (London, England) · 2024Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPericardial effusion (PE) is common in cancer patients, but the optimal therapeutic approach is not well defined. Percutaneous pericardiocentesis is less invasive than surgery, but its long-term effectiveness and safety have not been well documented.
objectivesThe goal of this study was to evaluate outcomes of cancer patients undergoing percutaneous pericardiocentesis for PE and assess the procedure's safety in patients with thrombocytopenia.
methodsCancer patients who underwent percutaneous pericardiocentesis for PE between November 2009 and October 2014 at the MD Anderson Cancer Center were included. Procedure-related complications, effusion recurrence rate, and overall survival were analyzed.
resultsOf 1,645 cancer patients referred for PE, 212 (13%) underwent percutaneous pericardiocentesis. The procedure was successful in 99% of the cases, and there were no procedure-related deaths. Four patients had major procedure-related bleeding that did not vary by platelet count <50,000/μl or ≥50,000/μl (p = 0.1281). Patients with catheter drainage for 3 to 5 days had the lowest recurrence rate (10%). Median overall survival was 143 days; older age (i.e., >65 years), lung cancer, platelet count <20,000/μl, and malignant pericardial fluid were independently associated with poor prognosis. Lung cancer patients with proven malignant effusions had a significantly shorter median 1-year survival compared with those with nonmalignant effusions (16.2% vs. 49.0%, respectively; log-rank test p = 0.0101). A similar difference in 1-year survival was not observed in patients with breast cancer (40.2% vs. 40.0%; log-rank test p = 0.4170).
conclusionsPercutaneous pericardiocentesis with extended catheter drainage was safe and effective as the primary treatment for PE in cancer patients, including in those with thrombocytopenia. Malignant PE significantly shortened the survival outcome of patients with lung cancer but not those with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.